logo-loader
viewNeovasc

Neovasc filing for a CE mark approval in Europe in 2020

Neovasc Inc. (NASDAQ:NVCN) (TSX: NVCN) CEO Fred Colen sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. The Vancouver, Canada-based company develops, manufactures and markets medical device products for the cardiovascular marketplace. Its products include the Reducer, for the treatment of refractory angina.

Quick facts: Neovasc

Price: 4.2 CAD

TSX:NVCN
Market: TSX
Market Cap: $46.76 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Cannabis stocks finish week in the red; Canaccord initiates...

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, was down 2.6% higher at 117.4 points. Elsewhere, the OTCQX Cannabis index fell 1.8% to 480.1 points. Buds today were Pharmacielo Ltd (CVE:PCLO), The Valens Company (CVE:VLNS) (OTCMKTS:VLNCF)....

1 day, 2 hours ago

2 min read